PD-L1 Antibody Engineering for Targeted Payload Internalization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for new PD-L1-binding agents that bind with high affinity, prevent PD-L1/PD-1 signaling, and deliver therapeutic payloads to PD-L1 expressing cells, as well as agents that can modulate immune responses for treating cancers, autoimmune disorders, and infections.
Innovation Solution
Development of PD-L1 binding agents comprising specific immunoglobulin heavy and light chain variable region polypeptides, which can target PD-L1 expressing cells, deliver therapeutic payloads, and modulate immune responses by blocking or promoting PD-L1/PD-1 signaling, and cause cellular internalization of the PD-L1 binding agent complex.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing PD-L1 antibodies (atezolizumab, durvalumab, avelumab) are used, then PD-L1/PD-1 signaling is blocked, but high affinity binding and effective payload delivery are not achieved
Solution Approach 1:
The patent modifies the antibody structure by engineering specific amino acid substitutions in the variable regions (e.g., HCDR3 and LCDR3 modifications) to enhance binding affinity parameters. These parameter changes in the molecular structure directly improve both affinity and payload delivery effectiveness without compromising manufacturability
Solution Approach 2:
The invention creates composite structures by conjugating therapeutic payloads (chemotherapeutic agents, toxins, or radioisotopes) to the PD-L1 binding antibody through chemical linkers. This composite approach combines the high specificity of the antibody with the therapeutic potency of the payload, achieving effective targeted delivery that neither component could achieve alone
2Reliability
If PD-L1 binding agents are developed for cancer treatment, then immune response is enhanced, but autoimmune disorders may be exacerbated
Solution Approach 1:
The patent employs highly specific epitope targeting where the engineered antibodies bind to particular local regions (epitopes) on the PD-L1 protein structure. This localized binding specificity ensures that immune enhancement occurs only at the intended molecular interface, reducing off-target effects and autoimmune activation while maintaining therapeutic efficacy against tumors
Solution Approach 2:
The antibody serves as an intermediary molecule that selectively modulates the PD-L1/PD-1 interaction. By controlling the timing, location, and magnitude of immune activation through this intermediary, the therapy enhances anti-tumor immunity while allowing regulatory mechanisms to prevent excessive autoimmune responses
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The PD-L1 binding agents effectively target and internalize PD-L1, enabling the delivery of therapeutic payloads and modulating immune responses, providing a therapeutic approach for treating various diseases and disorders.
Implementation Method 1
PD-L1 binding agents comprising an immunoglobulin heavy chain variable region polypeptide and an immunoglobulin light chain variable region polypeptide
Data Source
AI summary
The invention relates to programmed death-ligand 1 (PD-L1) binding agents, nucleic acids comprising the inventive binding agents, vectors and cells comprising the inventive nucleic acids, and compositions thereof. The invention also relates to methods of producing the inventive binding agents, methods for treating a disease, disorder, or condition in a mammal, and methods for enhancing or reducing or inhibiting an immune response in a mammal.